Episode 60: The SUCCESSOR-2 Trial in Myeloma

I am joined by the amazing Dr. Paul Richardson from the Dana-Farber Cancer Institute to discuss the SUCCESSOR trial that was presented at EHA. This trial discusses CELMoDs by highlighting a landmark randomized Phase 3 clinical study evaluating the oral medication mezigdomide combined with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. Results show the regimen significantly improves progression-free survival. Dr. Richardson puts this data into perspective. A must-watch on YouTube and listen here